What are the similarities and differences between shengnuo biotechnology companies + CDMO companies? Who has more potential in the future?
Recently, Science and Technology has ushered in a peptide pharmaceutical companyshengnuo biotechnology.
It is estimated that people who are not in the pharmaceutical industry are all in the cloud, and they don’t know the difference between the two.
Almost all of shengnuo biotechnology business is peptide drugs, mainly peptide raw materials and peptide preparations. The peptide CDMO business has just begun to exert its strength; peptide drug companies are currently mostly generic drugs, and the patent period of many blockbuster peptide drugs is coming soon. During this period, there is room for imagination.
Compared with small molecule drugs, peptide drugs are more difficult to produce on a large scale, but the approval rate is higher and the research and development cycle is shorter, and it has gradually become a research and development hotspot.
“Polypeptide” is a type of compound formed by a number of amino acids connected by dehydration and condensation to form peptide bonds, and its size is between small molecules and proteins. Generally, a molecule with less than 100 amino acids is called a polypeptide, and a molecule with more than 100 amino acids is called a protein.
Polypeptides are biologically active substances involved in various cell functions in organisms and are indispensable participants in life activities.
At present, more than 7,000 natural polypeptides have been discovered, involving hormones, nerves, cell growth and reproduction and other fields. Participate in and regulate the functions of various systems, organs and cells in the human body. Various human endocrine hormones, such as thyroxine, insulin, pituitary hormones, neuropeptides, enkephalins, growth factors, luteinizing hormones, etc., are all peptides
At present, peptides have been widely used in many fields such as medicine, food, health products, cosmetics, biological materials, and biological pesticides. Among them, the applications of peptides in the medical field mainly include peptide drugs, peptide vaccines, peptide diagnostic reagents, etc.
Compared with general small molecule chemicals, it has higher activity and stronger selectivity, and has obvious advantages in the treatment of complex diseases;
Compared with protein drugs, peptide drugs have the advantages of relatively good stability, high purity, low production cost, low immunogenicity or no immunogenicity.
The overall peptide drug is a good combination of the advantages of small molecule chemical drugs and protein drugs. It has the advantages of good stability, strong specificity, low impurities, and good curative effect. And because the peptide itself is a compound composed of amino acids, its metabolites are amino acids , Generally, there are no side effects or very few side effects on the human body.
Polypeptide drugs have a relatively high success rate, novel structures, and a wide range of sources. Compared with 4% of small molecule drugs that can enter phase I clinical trials, the rate of peptide drugs entering phase I clinical trials is as high as 17%, and the average cycle of peptide drug development is And the time from clinical trials to FDA approval is also shorter than that of small molecule drugs
After 2000, peptide drugs have increasingly become one of the hotspots of global new drug research and development.
The number of therapeutic peptide drugs on the market has increased rapidly. Up to now, an average of about 3 new peptide drugs have been approved for marketing each year.
As of September 2018, there are more than 70 kinds of peptide drugs worldwide. Peptide drugs have been approved for listing. About 200-300 peptide drugs are in clinical trials. Large multinational pharmaceutical companies have increased their investment in peptide drugs through acquisitions or mergers and acquisitions.
“At the same time, peptide drugs also have the disadvantages of high production cost and inconvenient administration. At present, chemical synthesis is the main way for the large-scale production of peptide drugs.
However, the chemical synthesis method is fast and flexible, but the cost is relatively high when scaled up production. The international market for some large-species APIs is as high as 250,000-500,000 US dollars per kilogram, and the cost of small-species APIs is thousands of US dollars per gram, and the price is relatively high.
Polypeptide drugs have a large molecular weight and a short half-life.
They are easily decomposed by enzymes in the body and are difficult to absorb through the digestive system. They are usually administered by injection. Therefore, peptide drugs are currently mainly used in acute and chronic diseases.
General surgical treatment is a one-time treatment. Octreotide acetate, somatostatin, terlipressin acetate for emergency hemostasis in the digestive tract, bivarudine, eptifibatide and nesiritide for cardiovascular and cerebrovascular diseases, carbetocin for obstetrics In addition, peptide drugs are also widely used in immunology, diabetes, orthopedics, tumors, and rare diseases lacking treatment methods.
The market scale of peptide preparations in my country in 2017 was US$1.74 billion, which is still far behind foreign countries. From the perspective of competition, there are nearly 100 peptide companies in my country, but the products of domestic peptide preparation companies are mostly imitating foreign peptide drugs that have passed the patent protection period or have not applied for a patent in my country.
The competition is concentrated on thymopentin, thymus method, and growth. The major peptide varieties such as statin are mainly immunization and emergency hemostatic drugs, and the competition in the industry is fierce. In contrast, leuprorelin, liraglutide, bivaluridine and other specialty varieties with few market competitors and newly expired patents have experienced rapid growth in sales.
The expiration of multiple peptide drugs with over $1 billion in the world is coming soon!
The compound growth rate of peptide drugs in my country exceeds 23%, and there is huge room for the treatment of chronic diseases in the future
As of 2017, there are more than 80 peptide drugs approved worldwide, of which the anti-tumor field has the largest number (30%), followed by the digestive tract field (14%), the diabetes field (13%) and rare diseases (11%).
Many peptide drugs have become varieties with an annual value of over hundreds of millions of dollars in just one or two years after being marketed. In 2016, there were 6 peptide drugs with annual sales of more than 1 billion U.S. dollars in the world-Teva Pharmaceuticals (TEVA) glatiramer, which has accounted for 20% of the multiple sclerosis market, with sales exceeding 4.2 billion U.S. dollars; Novo Nordisk Liraglutide is used to treat type II diabetes, with sales exceeding US$2.8 billion.
At the same time, 2014-2022 is the peak period for patent expiration of heavy peptide drugs. Liraglutide, glatiramer, teriparatide, goserelin, exenatide, etc. Series of blockbuster products, the market potential of peptide generic drugs in the future is also very considerable.
In 2018, the global peptide drug market reached 28.5 billion U.S. dollars, accounting for only 21.9% of the market. However, the compound growth rate from 2010 to 2018 exceeded 8%, which was approximately twice the overall growth rate of the global drug market.
Although the peptide drug market in my country started late, the compound growth rate of peptide drugs in my country from 2009 to 2017 reached 23.12%.
At present, there are more than 40 peptide drugs on the market in my country. Among them, immune drugs are the only one, accounting for more than 50% of the domestic market; The digestive tract and anti-tumor fields are next, each accounting for about 20%. The overall market is dominated by primary products and has not yet entered the mature stage. It is mainly short-term medication and emergency drugs. Oncology, orthopedics (osteoporosis treatment), diabetes and other chronic disease treatments account for only 26% of the market share, and there are still many Great room for development.
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
There are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.